Clinical investigators have also recognized that STAT3 inhibition as monotherapy is unlikely to demonstrate an improvement in survival for the vast majority of GBM patients, and, as such, the results of trials investigating STAT3 inhibition with conventional radiation (NCT03514069) and chemotherapy (NCT02315534) are eagerly awaited. Here, STAT3 is linked to glioblastoma.